Welcome to our dedicated page for Neuropace SEC filings (Ticker: NPCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroPace, Inc. SEC filings document the company's medical-device business, Nasdaq-listed common stock and public-company reporting obligations for the RNS System epilepsy therapy. Form 8-K reports cover operating results, financial condition, corporate updates, material agreements, clinical or regulatory disclosures, and executive or compensation-related events.
Proxy filings describe NeuroPace governance matters, including annual meeting proposals, director elections, auditor ratification and stockholder voting mechanics. The filing record also provides formal disclosure on capital structure, officer transitions, separation or consulting arrangements, and risk areas associated with commercialization, clinical evidence and regulatory oversight of neurostimulation devices.
Joseph Lacob, Director at NeuroPace, reported multiple acquisitions of common stock through the company's non-employee director compensation policy in lieu of quarterly retainer fees from June 2023 to June 2025.
Key transactions include:
- Nine separate acquisitions totaling 11,696 shares at prices ranging from $4.49 to $13.20
- Most recent acquisition: 1,080 shares at $10.41 on June 21, 2025
- Current direct ownership: 12,080 shares
- Significant indirect ownership through: - Lacob Ventures LLC: 128,174 shares - LCT18 Investments: 223,554 shares
Total beneficial ownership (direct and indirect) amounts to 363,808 shares, demonstrating substantial insider stake in the company. All direct acquisitions were made as compensation for board service rather than open market purchases.
NeuroPace director Frank M. Fischer reported multiple acquisitions of common stock through the company's non-employee director compensation policy in lieu of quarterly retainer fees from June 2023 to June 2025. Key transactions include:
- Most recent acquisition: 2,281 shares at $10.41 per share on June 21, 2025
- Largest acquisition: 4,469 shares at $4.49 per share on June 30, 2023
- Total shares accumulated: Increased position from 570,126 to 589,531 shares
- Share price range: $4.49 to $13.20 across nine quarterly acquisitions
All transactions were direct ownership acquisitions, with no derivative securities involved. The consistent pattern of stock acquisitions in lieu of cash compensation demonstrates the director's long-term alignment with shareholder interests and confidence in the company's future.